Morinidazole (R enantiomer)

    
98%

Morinidazole (R enantiomer)

源叶(MedMol)
S87133 一键复制产品信息
898230-59-6
C11H18N4O4
270.28502
货号 规格 价格 上海 北京 武汉 南京 购买数量
S87133-5mg 98% ¥550.00 货期:2-3天 - - -
S87133-10mg 98% ¥900.00 货期:2-3天 - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品

产品介绍

(R)-Morinidazole is an orally active and 5-nitroimidazole antimicrobial agent that undergoes extensive metabolism in humans via N+-glucuronidation and sulfation. (R)-Morinidazole can be used for bacterial infections research including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria

产品描述: (R)-Morinidazole is an orally active and 5-nitroimidazole antimicrobial agent that undergoes extensive metabolism in humans via N+-glucuronidation and sulfation. (R)-Morinidazole can be used for bacterial infections research including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria
靶点: organic anion transporter
体外研究: (R)-Morinidazole can be metabolized to N+-glucuronide of S-Morinidazole R enantiomer [M8-1] and N+-glucuronide of (R)-Morinidazole [M8-2] via N+-glucuronidation, and sulfate conjugate of (R)-Morinidazole [M7] via sulfation. M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (Km=28.6 and 54.0 μM, respectively), M8-1 and M8-2 are the substrates for OAT3. (R)-Morinidazole shows activity against Trichomonas vaginalis and Entamoeba histolytica in vitro, with MIC values of 2 μg/mL and 3 μg/mL, respectively
体内研究: (R)-Morinidazole (20 mg/kg or 25 mg/kg; p.o.; single dose) inhibits Trichomonas vaginalis and Entamoeba histolytica in vivo in rats with EC50s of 20 mg/kg and 25 mg/kg, respectively. (R)-Morinidazole (50 mg/kg; i.v.; 0.25, 0.75, 1.5 h) shows a different concentration in tissues after intravenous injection, with a higher concentration in liver, kidney, plasma than lung, heart, and spleen in mice Animal Model: Renal failure model in SD rats (180-220 g) Dosage: 50 mg/kg Administration: Intravenous injection; sacrificed rats at 0.25, 0.75, and 1.50 hours after dose administration Result: Increased plasma exposures slightly compared with control.
参考文献: 1. Zhong K, et al. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearanceof the conjugated metabolites. Antimicrob Agents Chemother. 2014 Jul;58(7):4153-61. 2. Kong F, et al. Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic Toxins. Drug Metab Dispos. 2017 Jun;45(6):593-603. 3. Lu Aifeng, et al. Application of α-(morpholine-1-yl)methyl-2-methyl-nitroimidazole-1-ethanol as anti-trichomonal agent and amebacide: China, CN1981764[P]. 2007-06-20.
溶解性: Soluble  in  DMSO
保存条件: -20℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 3.7 ml 18.499 ml 36.998 ml
5 mM 0.74 ml 3.7 ml 7.4 ml
10 mM 0.37 ml 1.85 ml 3.7 ml
50 mM 0.074 ml 0.37 ml 0.74 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×

相关产品